Supernus Pharmaceuticals, Inc. (SUPN) Financial Statements
Supernus Pharmaceuticals, Inc. (SUPN) reported trailing twelve-month revenue of $830.4M (up 24.9% year on year) and net income of -$109.9M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $18.8M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 2.4B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26. Results for the next quarter were released 19 Oct; these figures move once the 10-Q is filed.
| Line | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.01 | 0.09 | 0.15 | 0.22 | 0.30 | 0.41 | 0.39 | 0.52 | 0.58 | 0.67 | 0.61 | 0.66 | 0.72 | 0.83 | |
| Gross profit | — | 0.01 | 0.09 | 0.14 | 0.20 | 0.29 | 0.39 | 0.38 | — | 0.50 | 0.58 | 0.52 | 0.58 | 0.64 | 0.73 | |
| Research & development | 0.02 | 0.02 | 0.02 | 0.03 | 0.04 | 0.05 | 0.09 | 0.07 | 0.08 | 0.09 | 0.07 | 0.09 | 0.11 | 0.11 | 0.13 | |
| Operating income | -0.04 | -0.06 | -0.01 | 0.02 | 0.05 | 0.10 | 0.14 | 0.15 | 0.17 | 0.09 | 0.05 | -0.01 | 0.08 | -0.06 | -0.13 | |
| Pre-tax income | -0.05 | -0.09 | -0.01 | 0.01 | 0.05 | 0.10 | 0.14 | 0.15 | 0.17 | 0.07 | 0.06 | 0.00 | 0.10 | -0.05 | -0.12 | |
| Income tax | 0.00 | 0.00 | 0.00 | 0.00 | -0.04 | 0.04 | 0.03 | 0.03 | 0.04 | 0.02 | 0.00 | 0.00 | 0.02 | -0.01 | -0.01 | |
| Net income | -0.05 | -0.09 | -0.01 | 0.01 | 0.09 | 0.06 | 0.11 | 0.11 | 0.13 | 0.05 | 0.06 | 0.00 | 0.07 | -0.04 | -0.11 | |
| Diluted EPS ($) | -2.72 | -2.90 | -0.26 | 0.28 | 1.76 | 1.08 | 2.05 | 2.10 | 2.36 | 0.98 | 1.04 | 0.02 | 1.32 | -0.68 | -1.92 | |
| Diluted shares (bn) | 0.017 | 0.032 | 0.042 | 0.051 | 0.052 | 0.053 | 0.054 | 0.054 | 0.054 | 0.054 | 0.062 | 0.056 | 0.056 | 0.056 | — |
USD billions · SEC XBRL
Supernus Pharmaceuticals, Inc. — questions
- What is Supernus Pharmaceuticals, Inc.'s revenue?
- $830.4M over the twelve months to 2026-06-30, up 24.9% year on year, from its 10-Q and 10-K filings.
- What is Supernus Pharmaceuticals, Inc.'s net income?
- -$109.9M over the twelve months to 2026-06-30.
- What is Supernus Pharmaceuticals, Inc.'s free cash flow?
- $18.8M over the twelve months to 2026-06-30.
- What are Supernus Pharmaceuticals, Inc.'s diluted earnings per share?
- $-1.92 over the twelve months to 2026-06-30.
Every figure on this page comes from Supernus Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.